A study in which PARP 1/2 inhibitor BGB-290 was combined with the anti-PD-1 antibody BGB-A317 to treat advanced PC patients found that 1 subject experienced PR while 2 achieved SD. This evidence concerns the gene PDCD1 and pachyonychia congenita.